Intro Pullout Text Widget

RMD Open

is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 5.806
Citescore: 7.1
All metrics >>

RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

It is an online only open access journal that aims to provide rapid publication of research through a continuous publication model. All submitted content is subject to peer review prior to publication. Published work is free to read.

RMD Open is an official journal of EULAR.

Listen to the ARD and RMD Open podcast and subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts and Spotify.

You can keep up with the latest news via Twitter and Facebook.

Editorial team

Current Issue

New Editor-in-Chief: Professor Gerd Burmester

BMJ and EULAR are delighted to announce that Professor Gerd Burmester has been appointed as the new Editor-in-Chief for RMD Open.

Professor Burmester was the Director of the Department of Rheumatology and Clinical Immunology at the Charité Universitätsmedizin Berlin until very recently and is now a Senior Professor at this institution. He is a former President of EULAR. Since 2017 he has been President of the Board of Trustees of the FOREUM Foundation for Research in Rheumatology.

Professor Burmester has been an active supporter of RMD Open since its inception and we're excited that he has agreed to take the journal forward into its next stage of development.

Intro Pullout Text Widget

RMD Open

New Editor-in-Chief: Professor Gerd Burmester

Latest Articles

Spondyloarthritis:

Endothelial dysfunction and increased carotid intima–media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors

Epidemiology:

Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database

Rheumatoid arthritis:

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database

Rheumatoid arthritis:

Meaning of patient global assessment when joint counts are low in rheumatoid arthritis

Crystal arthropathies:

Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial

Why submit to RMD Open?

RMD Open

Most Read Articles

Miscellaneous:

Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

Rheumatoid arthritis:

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies

Infections:

Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey

Psoriatic arthritis:

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes

Crystal arthropathies:

High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis

COVID-19 Content

LETTER:

Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination

INFECTIONS:

Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses

INFECTIONS:

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)

AUTOINFLAMMATORY DISORDERS:

COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases

INFECTIONS:

Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?